基于网络药理学和分子对接技术探讨五苓散 治疗肥胖2型糖尿病的作用机制

摘要/Abstract

摘要： 目的：通过网络药理学和分子对接技术探讨五苓散治疗肥胖2型糖尿病（T2DM）的作用机制。方法：利用TCMSP数据库收集五苓散各药味的化学成分及对应靶点；通过OMIM、Drungbank和Denecards数据库整理肥胖T2DM的有关靶点；在Venny平台绘制成分-疾病靶点韦恩图及下载交集靶点文件；借助Cytoscape3.7.1构建五苓散潜在活性成分-交集靶点网络，由CytoNCA得到关键靶点；利用关键靶点反向对接得到五苓散关键成分；通过微生信网对关键靶点做GO功能与KEGG通路富集分析，再构建“成分-靶点-通路”网络；利用Sybyl-X2.0对关键成分与关键靶点进行分子对接验证。结果：得到五苓散135个潜在活性成分，包含168个潜在作用靶点，与2 111个肥胖T2DM的相关靶点交集后，获得85个共有靶点；拓扑分析得到30个关键靶点，反向对接得到关键成分68个；五苓散治疗肥胖T2DM主要涉及TNF、IL6、INS、IL1B、PTGS2、JUN等靶点；涉及药物应答、细胞间的信号传递、细胞外环境和细包表面、肾上腺素结合、类固醇激素受体活性等过程以及恰加斯病（Chagas disease）、胰岛素抵抗（Insulin resistance）、Toll样受体信号通路（Toll-like receptor signaling pathway）、肿瘤坏死因子信号通路（TNF signaling pathway）等通路；分子对接显示TNF、IL6、INS与27个关键成分有较强的相互作用关系，与4个成分有强烈的相互作用。结论：五苓散治疗肥胖T2DM针对的靶点和通路多与炎症反应和糖脂代谢有关。

关键词: font-size:medium, ">五苓散；肥胖2型糖尿病；网络药理学；分子对接

Abstract: Objective：Using network pharmacology and molecular docking technology to explore the mechanism of Wuling San in treating obese type 2 diabetes mellitus(T2DM). Methods：The chemical components and corresponding targets of Wuling San were collected by TCMSP database. The targets related to obese T2DM were sorted out through OMIM， TTD， Drungbank and Disgent databases; Draw Venny maps of component targets and obese T2DM targets on Venny platform and download intersection target file; The network of "potential active components of WulingSan - intersection targets" was constructed with Cytoscape3.7.1， and the key targets were obtained by CytoNCA. The key components were obtained by reverse docking the key target. GO function annotation and KEGG signal pathway enrichment analysis were performed viamicro bioscience network. the "component target pathway" network constructed by Cytoscape 3.7.1 software. Sybyl-x2.0 was used to verify the molecular docking between key components and key targets. Results： 135 potential active components of Wuling San were obtained， including 168 potential targets， which were combined with 2 111 related targets of obese T2DM， and 85 common targets were obtained. 30 key targets were screened by CytoNCA， and 68 key components were obtained by reverse docking. Wuling San mainly involves TNF， IL6， INS， IL1B， PTGS2， JUN and other targets in treating obese T2DM. It involves the processes of drug response， signal transmission between cells， extracellular environment and the surface of sachet， adrenaline binding， steroid hormone receptor activity and other pathways， as well as Chagas disease， Insulin resistance， Toll-like receptor signaling pathway， tumor necrosis factor signaling pathway and so on. Molecular docking showed that TNF， IL-6 and INS had strong interaction with 27 key components and strong interaction with 4 components.Conclusion：The targets and pathways of Wuling San in improving obese type 2 diabetes are mostly related to inflammatory reaction and glucose and lipid metabolism.

Key words: Wuling San, Obese type 2 diabetes mellitus, Network pharmacology, Molecular docking

中图分类号:

康佳, 贺嫣然, 郁晶怡, 张婉晴, 王慧, 林雅丽, 刘应蛟, 樊启猛, 刘红宁, . 基于网络药理学和分子对接技术探讨五苓散治疗肥胖2型糖尿病的作用机制[J]. 中国药物评价, 2022, 39(3): 232-240.

KANG Jia, HE Yan-ran, YU Jing-yi, ZHANG Wan-qing, WANG Hui, LIU Ying-jiao, FAN Qi-meng, LIN Ya-li, LIU Hong-ning, . Exploring the Mechanism of Wuling San in Treatment of Obese Type 2 Diabetes Mellitus Based on Network Pharmacology and Molecular Docking[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2022, 39(3): 232-240.

参考文献

[1]杨璐瑶，胡琼英. 中药治疗2型糖尿病的研究进展[J]. 中国中西医结合杂志， 2020， 40(8): 1007-1011.
     [2]健康中国2020战略研究报告委会. “健康中国2020”战略研究报告[M]. 北京: 人民卫生出版社， 2012.
     [3]陈颖，夏明锋，李小英. 体脂分布与糖尿病风险[J].中华糖尿病杂志，2017，4：3.
     [4]中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中国实用内科杂志， 2018， 38(4): 292-344.
     [5]乔飞飞，王莉，于英华. 基于CiteSpace的中医药论治肥胖2型糖尿病的可视化分析[EB/OL]. [2022-01-16]. http://kns.cnki.net/kcms/detail/21.1187.R.20211201.2130.012.html.
     [6]李红梅. 五苓散加减治疗肥胖型2型糖尿病的效果分析[J]. 临床研究， 2018， 26(7): 152-154.
     [7]虞寒芬. 五苓散加味联合二甲双胍治疗肥胖型2型糖尿病48例疗效观察[J]. 新中医， 2014， 46(10): 92-94.
     [8]李梢，张博. 中药网络药理学:理论、方法与应用(英文)[J]. 中国天然药物， 2013， 11(2): 110-120.
     [9]世界中医药学会联合会. 网络药理学评价方法指南[J]. 世界中医药， 2021， 16(4): 527-532.
     [10]牛明，张斯琴，张博，等，《网络药理学评价方法指南》解读[J].中草药， 2021， 52(14): 4119-4129.
     [11]武永乐，尚宏伟，孙广永，等. 小鼠脂肪组织中免疫细胞分离方法的优化及亚群在肥胖小鼠中的作用[J]. 首都医科大学学报， 2021， 42(4): 559-567.
     [12]陈琴华，余飞，王红梅，等. 白术内酯Ⅰ、Ⅱ、Ⅲ对炎性巨噬细胞细胞因子表达的影响[J]. 中国药师， 2017， 20(12): 2112-2116.
     [13]李丽莎，徐小妹，卢雪花，等. 泽泻对高脂高糖饮食大鼠肠道菌群多样性的影响[J]. 中国微生态学杂志， 2019， 31(4): 396-401.
     [14]林文津，徐榕青，张亚敏，等. 泽泻不同提取物对SGC-7901细胞线粒体能量代谢的影响[J]. 中药新药与临床药理， 2014， 25(1): 36-39.
     [15]吴嘉朔，常晓燕，李壮壮，等. 泽泻汤降脂及抗炎作用分子机制研究进展[J]. 中国实验方剂学杂志， 2021， 27(2): 224-232.
     [16]吴振宁，祁龙凯，陈地灵. 茯苓提取物对高脂饮食致肠道菌群失调小鼠的影响[J]. 中国现代中药， 2020， 22(11): 1822-1829.
     [17]庞雅芬，黄明，李琳，等. 丹蒌片降低db/db小鼠肝脏脂肪生成及炎症反应改善胰岛素抵抗的作用研究[EB/OL]. [2022-01-03]. DOI:10.19540/j.cnki.cjcmm.20211220.401.
     [18]谷亚楠. 单纯性肥胖儿童胰岛素抵抗与IL-6、TNF-α、hs-CRP的关系[D]. 大连: 大连医科大学，2017.
     [19]张雅静，冯玲，赵伟，等. 促甲状腺素通过促进TNF-α分泌下调3T3-L1脂肪细胞的IRS-1表达[J]. 中华内分泌代谢杂志， 2014， 30(1): 65-68.
     [20]周立新，王兆艳，张颖，等. 血清TNF-α水平及体重指数与初发2型糖尿病老年患者胰岛素抵抗的相关性[J]. 中国老年学杂志， 2021， 41(18): 3923-3926.
     [21]Hetta H F . Visfatin Serum Levels in Obese Type 2 Diabetic Patients: Relation to Proinflammatory Cytokines and Insulin Resistance[J]. The Egyptian journal of immunology/Egyptian Association of Immunologists， 2018， 25(2): 141-151.
     [22]Tong Y， Zhang Y， Shan Z， et al. Improving high-fat diet-induced obesity and fatty liver by adipose tissue targeted delivery of vascular endothelial growth factor-B[J]. Life sciences， 2020， 253: 117677.
     [23]陈加玉，滕岩，杨明明. 炎症调控因子在糖尿病视网膜病变新生血管形成中的作用[J]. 国际眼科杂志， 2021， 21(8): 4.
     [24]丁剑锋. TO901317调控IL-1β/VEGF通路抑制糖尿病视网膜病变新生血管的机制探讨[D]. 石河子大学， 2021.
     [25]王岚淼. 化痰通络汤干预肥胖相关性高血压及对TLR4/NF-kB炎性信号通路影响的临床研究[D]. 山东中医药大学， 2020.
     [26]栾宁，刘丹，刘畅，等. LTBP2通过TLR4/NF-κB信号通路抑制糖尿病大鼠海马神经元凋亡[J]. 天津医药， 2021， 49(8): 812-817.
     [27]Wang M， Li S， Wang F， et al. Aerobic exercise regulates blood lipid and insulin resistance via the toll-like receptor 4-mediated extracellular signal-regulated kinases/AMP-activated protein kinases signaling pathway [J]. Mol Med Rep， 2018， 17(6): 8339-8348.
     [28]暴鹏，李雪，孙丽莎，等. 补阳还五汤抑制TLR4信号通路减轻db/db糖尿病小鼠周围神经病变炎症反应[J]. 山西医科大学学报， 2020， 51(2): 153-157.
     [29]李菊霜，包丽萍，胡双，等. 冬凌草甲素对2型糖尿病大鼠肾脏Toll样受体4介导免疫炎症信号通路的干预研究[J]. 中华糖尿病杂志， 2018， 10(12): 800-806.
     [30]李琳娜，李坚，贺熙乔，等. TLR4/MyD88/AMPK通路参与调节高脂饮食诱导的肥胖小鼠脂肪组织炎症和细胞凋亡[EB/OL]. [2021-11-23].http://kns.cnki.net/kcms/detail/22.1126.R.20210304.1720.002.html.
     [31]张瀚文. 中药复方益糖康通过TLR4/MyD88/NF-κB通路防治糖尿病大鼠视网膜病变的机制研究[D]. 辽宁中医药大学， 2021.
     [32]Poblete J， Ballinger M N， Bao S， et al. Macrophage HIF-1α mediates obesity-related adipose tissue dysfunction via interleukin-1 receptor-associated kinase M [J]. American journal of physiology. Endocrinology and metabolism， 2020，318(5):E689-E700.
     [33]王雅媛，梁凤霞，卢威，等.电针对肥胖胰岛素抵抗大鼠胰岛素敏感性及脂肪组织脂联素、抵抗素基因表达的影响[J].中国中医基础医学杂志，2021，27(09):1444-1450.
     [34]Maltarollo V G， Kronenberger T， Windshugel B， et al. Advances and challenges in drug design of PPARδ ligands[J]. Curr Drug Targets， 2018， 19(2): 144-154.
     [35]Guan J， Zhao M， He C， et al. Anti-Hypertensive Action of Fenofibrate via UCP2 upregulation mediated by PPAR activation in baroreflex afferent pathway[J]. Neurosci Bull， 2019， 35(1): 15-24.
     [36][Daisy C， Michelle R， Liana P A S， et al. The A allele of the UCP2 -866G/A polymorphism changes UCP2 promoter activity in HUVECs treated with high glucose[J]. Mol Biol Rep， 2019， 46(5): 4735-4741.
     [37]Ying K，Yan G，Dong y L， et al. Trans‐repression of NF-κB pathway mediated by PPARγ improves vascular endothelium insulin resistance[J]. J Cell Mol Med， 2018， 23(1): 1-11.
     [38]Wang R， Li D， Ouyang J， et al. Leonurine alleviates LPS-induced myocarditis through suppressing the NF-кB signaling pathway[J]. Clin Toxicol， 2019， 422: 1-13.
     [39]Lan T， Li Q， Chang M， et al. Lei-gong-gen formula granule attenuates hyperlipidemia in rats via cGMP-PKG signaling pathway[J]. Journal of Ethnopharmacology， 2020， 260(1): 112989.